CN1180775C - Compound stomatocase-treating capsule - Google Patents
Compound stomatocase-treating capsule Download PDFInfo
- Publication number
- CN1180775C CN1180775C CNB021256829A CN02125682A CN1180775C CN 1180775 C CN1180775 C CN 1180775C CN B021256829 A CNB021256829 A CN B021256829A CN 02125682 A CN02125682 A CN 02125682A CN 1180775 C CN1180775 C CN 1180775C
- Authority
- CN
- China
- Prior art keywords
- capsule
- stomatocase
- ulcer
- vitamin
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 31
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 10
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001380 cimetidine Drugs 0.000 claims abstract description 10
- 229960004503 metoclopramide Drugs 0.000 claims abstract description 10
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000282 metronidazole Drugs 0.000 claims abstract description 9
- 229960004618 prednisone Drugs 0.000 claims abstract description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 10
- 230000000306 recurrent effect Effects 0.000 abstract description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract description 4
- 208000007117 Oral Ulcer Diseases 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 2
- 229930003471 Vitamin B2 Natural products 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- 229960002477 riboflavin Drugs 0.000 abstract 2
- 235000019164 vitamin B2 Nutrition 0.000 abstract 2
- 239000011716 vitamin B2 Substances 0.000 abstract 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229960002079 calcium pantothenate Drugs 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 239000011726 vitamin B6 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 25
- 231100000397 ulcer Toxicity 0.000 description 25
- 230000035876 healing Effects 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 206010028034 Mouth ulceration Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039740 Screaming Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004755 lingual frenum Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940102542 prednisone 5 mg Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000005922 Glossalgia Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024570 Lip swelling Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940037348 metronidazole 200 mg Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010201 sheng-ji-san Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a compound stomatocase-treating capsule which belongs to the technical field of medicine. The capsule is composed of 11.6 to 232 mg of cimetidine, 11.6 to 232 mg of metronidazole, 0.3 to 6 mg of metoclopramide, 0.3 to 6 mg of prednisone, 0.23 to 4.6 mg of VB1(vitamin B1), 0.105 to 2.1 mg of VB2 (vitamin B2), 0.015 to 0.3 mg of VB 6 (vitamin B6), 0.78 to 15.6 mg of niacinamide and 0.07 to 1.4 mg of dextrorotation calcium pantothenate. The capsule of the present invention has the advantages of broad preparing raw material source, cheapness, no special abnormal taste or stimulation when orally taken, and good mouth feel and reduces medicine cost. The present invention is used by 3000 clinic acute and chronic recurrent oral ulcer patients to prove that the total effective rate reaches 100%, and no specific toxic or side reaction occurs.
Description
Technical field
The invention belongs to medical technical field, particularly a kind of compound stomatocase-treating capsule.
Background technology
Method to the oral cavity ulcer treatment is " Oral Science " used according to the undergraduate course five-year system clinical medicine system that Mao Zuyi edits at present.Divide local and the treatment of whole body two aspects.
One, topical therapeutic:
1. Chinese powder medicine, as nourishing yin shengjisan, XILEI SAN, the ice friend looses and waits that the part is deposited spreads.
2. oral ulcer medicine film, one for several times, with reference to calendar year 2001 December " Arzneibucs " published.
3. isolated ulcer also usable concentration is that 10wt% silver nitrate or 5wt% trichloroacetic acid etc. burn.
4. huge ulcer can be pressed the ulcer size with hydrocortisone acetate or the imperial suspension of powerful pine, be taken the circumstances into consideration infiltration injecting connective tissue under ulcer.
Two, whole body therapeutic:
1. Chinese traditional treatment:
Excess fire type: suitable clearing away heat-fire, removing heat from blood relieving constipation or heat-clearing and toxic substances removing, plus-minuss such as Liangge San, yun YINQIAO are selected in the removing heat from blood eliminating dampness by diuresis for use;
Asthenic fire type: should nourishing YIN and clearing away heat, suppressing the hyperactive liver nourishes blood or invigorating the spleen and regulating the stomach, QI invigorating dampness removing, can select LIUWEI DIHUANG WAN for use, the BUZHONG YIQI TANG plus-minus.
2. western medical treatment: the solid ferment medicine usefulness of classes such as prednisone, dexamethasone, take the circumstances into consideration to select for use immunosuppressant, as azathioprine, cyclophosphamide (side effect etc. is arranged); Select immunostimulant for use, transfer factor, gamma globulin etc.
By clinical observation, find that there is following several respects deficiency in this therapeutic scheme:
1. in theory this sick cause of disease, pathogenesis, pathological change are not still had unified understanding, make the therapeutic scheme target indeterminate, lack specificity.
2. mainly based on to the ill, cure the symptoms, not the disease in the western medicine aspect, and medicament selection is simple, no particularity, the therapeutic effect pain relieving is poor, and ulcer is difficult for healing or the easily recurrence of temporary transient healing back, and there is serious toxic and side effects in the part medicine, for human body causes unnecessary harm.
3. Chinese traditional treatment: be that to control with dialectical opinion be principle, a people one side, vary with each individual that dialectical error is arranged slightly, cause that easily the state of an illness increases the weight of, must under the professional instructs, use, and the preparation complexity, take, carry inconvenience, curative effect is difficult to determine.
4. the local medicine that uses has the abnormal flavour zest strong, and for the patient brings the suffering of illness that is difficult to accept, topical remedy is once elimination, and the state of an illness may be shown effect once more, does not reach the radical cure purpose.
Summary of the invention
The objective of the invention is provides a kind of compound stomatocase-treating capsule at existing deficiency in the oral ulcer treatment.
The inventor in conjunction with modern physiology, pathology, pharmacology, immunology progress, proposes the understanding of following several respects through clinical observation over 10 years to the oral cavity ulcer treatment:
1. in theory the cause of disease, pathogenesis aspect are thought when being mainly the shortage of trace element in the low and/or body of immune function of human body, and/or in the presence of extraneous factor (pH value reduction etc. in as hyperpyrexia antibacterial, viral infection, wound, burn, oral cavity), make oral mucosa lesion, being difficult in time, healing develops into ulcer, select western medicine at Therapeutic Principle's directiveness that the cause of disease, pathogenesis propose to control by Chinese medicine organic conception and dialectical opinion, thereby form with instruction of Chinese Medicine theory the method for western medicine.
2. selecting medicine is to strengthen immune function of human body, replenish the trace element that health is lacked, grow, promote that for mucosa ulcer healing provides the condition of general material, improve edema, allergy, the antibacterial of killing ulcer spot, virus that the ulcer part causes because of inflammation simultaneously, improve the stimulation of oral cavity inner acidic environment, thereby for ulcer healing provides good local environment, both organically combine, and make the timely pain relieving of ulcer, rapidly healing, and can make ulcer be difficult for recurrence, reach treating both the principal and secondary aspects of a disease.
3. selected medicine is all with reference to calendar year 2001 December " the practical Arzneibucs " published, through drug combination be selected drug dose all less than positive usual amounts, make the toxic and side effects of every kind of medicine be reduced to floor level, the infringement of avoiding medicine that human body is caused.
The composition of compound stomatocase-treating capsule of the present invention and content are:
Cimetidine 11.6-232mg metronidazole 11.6-232mg
Metoclopramide 0.3-6mg prednisone 0.3-6mg
VB
1(vitamin B
1) 0.23-4.6mg VB
2(vitamin B
2) 0.105-2.1mg
VB
6(vitamin B
6) 0.015-0.3mg nicotiamide 0.78-15.6mg
Dextro calcium pantothenate 0.07-1.4mg
With above nine kinds of medicines mix homogeneously after grinding, in incapsulating then, promptly prepare compound stomatocase-treating capsule of the present invention.
The preferred composition and the content of every compound stomatocase-treating capsule of the present invention are:
Cimetidine 58mg metronidazole 58mg
Metoclopramide 1.5mg prednisone 1.5mg
VB
1(vitamin B
1) 1.15mg VB
2(vitamin B
2) 0.525mg
VB
6(vitamin B
6) 0.075mg nicotiamide 3.9mg
Dextro calcium pantothenate 0.35mg
The characteristics of compound stomatocase-treating capsule of the present invention:
1. use through clinical 3000 routine acute and chronics, recurrent oral ulceration patient, healing time is the shortest 24 hours, and is the longest 10 days.Take dose: with the each 500mg of adult's (referring to more than 14 years old), twice of every day.Children's's (0-14 year) is oral at twice with per kilogram of body weight 20-25mg every day.With per 5 days be a course of treatment, 3,000 patients use, one of them course of treatment healing person be 93%, two the course of treatment healing person be 6.2%, three the course of treatment healing person be 0.8%; Total effective rate reaches 100%, does not see special toxicity, oral no specific peculiar smell and zest, good mouthfeel.
2. preparation raw material wide material sources, cheapness, cost of drugs is reduced.
3. the patient is easy to use, can be own according to the symptom of feeling, and age, body weight are pressed the medicine explanation and are selected medication, need not the professional instruct.
4. dosage form is a capsule-type, and is oral, easy to carry, is not subjected to condition restriction.
Compound stomatocase-treating capsule of the present invention improves whole body and oral cavity partial environment with human body immunity improving power, is used for the treatment of acute and chronic, recurrent oral ulceration and the double periodontitis of controlling, ulcerative colitis.Every capsules content of dispersion is 125mg.When using compound stomatocase-treating capsule of the present invention, should notice that (1) tuberculosis, diabetes, anemia of pregnant woman can take the circumstances into consideration decrement; (2) chickenpox, the careful usefulness of herpes zoster patient; (3) period in a medicine fasting raw food zest, sugar and the big diet of sugar content are based on light.
The specific embodiment
Embodiment 1:
Zheng * *, man, 47 years old, recurrent oral ulceration 10 years is surplus, annual outbreak several, it is surplus that each outbreak continues January, and fluid infusion support once is anti-to be felt, western medicine and treatment by Chinese herbs, poor effect, going to a doctor in this morbidity back on the 10th day, checks and see lingual frenum, the both sides mucosa respectively has the round ulcer of a diameter 3mm, the inboard mucosa of lower lip has the oval ulcer of diameter 4mm size, and is congested on every side, edema, local pain is through taking compound stomatocase-treating capsule of the present invention, press 500mg/ time (promptly 4), 2 times/day, pain relief after 12 hours, ulcer surface dwindles, the ulcer surface healing is followed up a case by regular visits to and was not seen recurrence in 1 year after 36 hours.
The component of compound stomatocase-treating capsule and content are:
Cimetidine 58mg metronidazole 58mg metoclopramide 1.5mg
Prednisone 1.5mg VB
11.15mg VB
20.525mg
VB
60.075mg nicotiamide 3.9mg dextro calcium pantothenate 0.35mg
With above nine kinds of medicines mix homogeneously after grinding, in incapsulating then, promptly prepare compound stomatocase-treating capsule of the present invention, every capsules content of dispersion is 125mg.
Embodiment 2:
Poplar * *, the woman, 30 years old, recurrent oral ulceration 10 years was surplus, whenever fever, lose eye, fatigue promptly shows effect, sky surplus each outbreak 20, once western medicines in treatment was invalid, went to a doctor in this morbidity back on the 7th day, checked that mouthful inboard mucosa of disgrace has the big aphtha of a diameter 6mm as follows, cheek inboard mucosa in a left side has the big aphtha of a diameter 4mm, congested on every side, local pain, ulcer surface has the yellow-white pseudomembrane, through taking compound stomatocase-treating capsule of the present invention, 500mg/ time, 2 times/day, pain relieving in 6 hours, ulcer surface dwindled in 12 hours, ulcer healing after 30 hours serve on 5 days transference cures.
The component of compound stomatocase-treating capsule and content are:
Cimetidine 58mg metronidazole 58mg metoclopramide 1.5mg
Prednisone 1.5mg VB
11.15mg VB
20.525mg
VB
60.075mg nicotiamide 3.9mg dextro calcium pantothenate 0.35mg
With above nine kinds of medicines mix homogeneously after grinding, in incapsulating then, promptly prepare compound stomatocase-treating capsule of the present invention, every capsules content of dispersion is 125mg.
Embodiment 3:
Zheng *, the woman, 4 months, body weight 6Kg, to refuse the breast prescription on individual diagnosis in more than two days of crying and screaming, the temperature of having a medical check-up is T37.20 ℃.Mind is clear, spirit is poor, it is normal to grow, reddened and swollen lips, and the saliva amount is many, and 3 of the big aphthas of the grain of rice are arranged in the last lip, and the tip of the tongue and lingual frenum root have 1 * 1mm
23 of big aphthas, blush, swelling on every side, oral VB
2It is invalid that local use ice friend looses, and gives the clothes compound stomatocase-treating capsule, measures with per kilogram 25mg every day and calculate, and divides secondary to take, and crying and screaming after 3 hours stops, feed, and the minimizing of saliva amount, oral cavity ulcer healing after 24 hours serve on recovery from illness on the two.
The component of compound stomatocase-treating capsule and content are:
Cimetidine 17mg metronidazole 83mg metoclopramide 3.1mg
Prednisone 5mg VB
14.0mg VB
22.014mg
VB
60.086mg nicotiamide 12.8mg dextro calcium pantothenate 1mg
With above nine kinds of medicines mix homogeneously after grinding, in incapsulating then, promptly prepare compound stomatocase-treating capsule of the present invention, every capsules content of dispersion is 125mg.
Embodiment 4:
Guo * *, the man, 12 years old, body weight 30Kg went to a doctor with glossodynia, feed difficulty in 5 days, checked and saw that respectively there is 2 * 2mm the tongue body both sides
2Big aphtha, blush slightly on every side, the lip of the tongue has blurred big or small 2 place's ulcer, intramuscular injection pioneer five, oral B
2Cydiodine, poor effect and going to a doctor.Give the clothes compound stomatocase-treating capsule, calculate (promptly 6 are divided each three of secondary) with per kilogram 25mg every day amount.Take pain relief in back 12 hours.Ulcer healing after 36 hours serve on recovery from illness on the three.
The component of compound stomatocase-treating capsule and content are:
Cimetidine 11mg metronidazole 58mg metoclopramide 6mg
Prednisone 0.3mg VB
10.3mg VB
22.1mg
VB
60.25mg nicotiamide 13.6mg dextro calcium pantothenate 0.1mg
With above nine kinds of medicines mix homogeneously after grinding, in incapsulating then, promptly prepare compound stomatocase-treating capsule of the present invention, every capsules content of dispersion is 125mg.
Embodiment 5:
Pueraria lobota * *, the man, 92 years old, with oral cavity pain, take food a difficult week, through fluid infusion, use KOUQIANG KUIYANG MO, oral Wu too stomatocase-treating capsule treats the commentaries on classics prescription on individual diagnosis of not getting better.Check, see that respectively there is 2 * 2mm the tongue both sides
2Big aphtha, surperficial HUANGBAI(sic), there is 3 * 3mm red slightly on every side right cheek inboard
2Big aphtha is given the clothes compound stomatocase-treating capsule, and 500mg/ time, every day 2 times, pain relief can be taken food after 24 hours, and ulcer was dwindled in 48 hours, serve on recovery from illness in 5 days.Follow up a case by regular visits to and do not see recurrence in 1 year.
The component of compound stomatocase-treating capsule and content are:
Cimetidine 230mg metronidazole 200mg metoclopramide 6mg
Prednisone 5mg VB
1N 0.2mg VB
20.105mg
VB
60.3mg nicotiamide 15mg dextro calcium pantothenate 1.4mg
With above nine kinds of medicines mix homogeneously after grinding, in incapsulating then, promptly prepare compound stomatocase-treating capsule of the present invention, every capsules content of dispersion is 125mg.
Claims (2)
1. compound stomatocase-treating capsule is characterized in that: following nine kinds of medicines after grinding, by its content mix homogeneously, in incapsulating then, are promptly prepared compound stomatocase-treating capsule,
Cimetidine 11.6-232mg metronidazole 11.6-232mg
Metoclopramide 0.3-6mg prednisone 0.3-6mg
VB
1 0.23-4.6mg VB
2 0.105-2.1mg
VB
60.015-0.3mg nicotiamide 0.78-15.6mg
Dextro calcium pantothenate 0.07-1.4mg.
2. capsule as claimed in claim 1 is characterized in that: the composition of described compound stomatocase-treating capsule and content are:
Cimetidine 58mg metronidazole 58mg
Metoclopramide 1.5mg prednisone 1.5mg
VB
1 1.15mg VB
2 0.525mg
VB
60.075mg nicotiamide 3.9mg
Dextro calcium pantothenate 0.35mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021256829A CN1180775C (en) | 2002-07-29 | 2002-07-29 | Compound stomatocase-treating capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021256829A CN1180775C (en) | 2002-07-29 | 2002-07-29 | Compound stomatocase-treating capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1387852A CN1387852A (en) | 2003-01-01 |
| CN1180775C true CN1180775C (en) | 2004-12-22 |
Family
ID=4745633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021256829A Expired - Fee Related CN1180775C (en) | 2002-07-29 | 2002-07-29 | Compound stomatocase-treating capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1180775C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287561A (en) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | Pharmaceutical composition for treating ulcerative colitis |
-
2002
- 2002-07-29 CN CNB021256829A patent/CN1180775C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1387852A (en) | 2003-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1180775C (en) | Compound stomatocase-treating capsule | |
| CN1868529A (en) | Medicine composition for treating gastritis, and its prepn. method | |
| CN1109553C (en) | Chinese-medicinal capsule for treating diabetes | |
| CN1781538A (en) | Chinese medicine preparation for treating nephritis and nephrotic syndrome | |
| CN1319587C (en) | Medicine powder for liver and spleen diseases | |
| CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN1544047A (en) | Chinese traditional medicine composition for treating cancer and its preparation | |
| CN1872306A (en) | Preparation of Chinese traditional medicine for treating baby's cough, and preparation method | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN108066706B (en) | Traditional Chinese medicine jaundice-removing plaster for treating icteric hepatitis | |
| CN1883666A (en) | Pharmaceutical composition for treating nephritis | |
| CN1242766C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN1251723C (en) | Pharmaceutical composition for treating idiopathic thrombocytopenic purpura of blood heat type and its preparing process | |
| CN1192365A (en) | Traditional Chinese medicine for treating mastosis | |
| CN1739673A (en) | Hypertension treating Chinese medicine composition | |
| CN1210049C (en) | Chinese medicine composition for treating diabetes | |
| CN101066343A (en) | Externally applied Chinese medicine for treating tonisillitis and lymphnoditis and its prepn process | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN1915324A (en) | Pediatric Fupi preparation and preparation method thereof | |
| CN1513539A (en) | Preparation technology of supplementing kind capsule | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1220507C (en) | Compound preparation for treating child diarrhea and its preparation method | |
| CN1239179C (en) | Chinese medicine for treating diabetes and preparation method therefor | |
| CN116549591A (en) | A kind of traditional Chinese medicine combination for treating stomachache and application thereof | |
| CN1465357A (en) | Chinese patent drug for treating chronic gastritis and chronic gastric ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |